Home » Stocks » Alkermes

Alkermes PLC (ALKS)

Stock Price: $18.56 USD -0.15 (-0.78%)
Updated Aug 10, 2020 2:15 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.95B
Revenue (ttm) 1.16B
Net Income (ttm) -126.32M
Shares Out 159.04M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE 156.25
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $18.56
Previous Close $18.70
Change ($) -0.15
Change (%) -0.78%
Day's Open 18.77
Day's Range 18.14 - 18.77
Day's Volume 445,348
52-Week Range 11.98 - 23.22

More Stats

Market Cap 2.95B
Enterprise Value 2.81B
Earnings Date (est) Oct 21, 2020
Ex-Dividend Date n/a
Shares Outstanding 159.04M
Float 157.34M
EPS (basic) -0.8
EPS (diluted) -0.80
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.92M
Short Ratio 6.44
Short % of Float 9.40%
Beta 1.43
PE Ratio n/a
Forward PE 156.25
P/FCF Ratio n/a
PS Ratio 2.54
PB Ratio 2.79
Revenue 1.16B
Operating Income -134.59M
Net Income -126.32M
Free Cash Flow -52.82M
Net Cash 141.78M
Net Cash / Share 0.89
Gross Margin 85.27%
Operating Margin -11.59%
Profit Margin -10.90%
FCF Margin -4.55%
ROA -4.26%
ROE -11.73%
ROIC -7.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 1
Overweight 0
Hold 10
Underweight 0
Sell 1

Analyst Consensus: Hold

Price Target

$19.64*
(5.85% upside)
Low
15.0
Current: $18.56
High
26.0
Target: 19.64
*Average 12-month price target from 11 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142012201120102009
Revenue1,1711,094903746628619576390187178
Revenue Growth7.01%21.13%21.15%18.68%1.54%7.51%47.59%108.95%4.69%-
Gross Profit991918749614489443405262134129
Operating Income-175-99.13-148-209-224-87.1481.81-88.28-45.63-43.03
Net Income-197-139-158-208-227-30.0624.98-114-45.54-39.63
Shares Outstanding15715515315114914513211595.6194.84
Earnings Per Share-1.25-0.90-1.03-1.38-1.52-0.210.18-0.99-0.48-0.42
Operating Cash Flow72.0899.2819.19-63.80-40.3611.14127-2.48-5.91-12.25
Capital Expenditures-90.04-68.92-51.14-43.46-52.3410.71-22.02-16.95-9.01-15.54
Free Cash Flow-17.9730.36-31.95-107-92.7021.85105-19.44-14.91-27.79
Cash & Equivalents535539434497535631221190201281
Total Debt291279281284350356369444-51.04
Net Cash / Debt244260152214185275-148-254201230
Assets1,8051,8251,7971,7261,8561,9191,4701,435452516
Liabilities72065459451754152251858160.43103
Book Value1,0851,1711,2031,2091,3141,397952854392413
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Alkermes PLC
Country Ireland
Employees 2,235
CEO Richard F. Pops

Stock Information

Ticker Symbol ALKS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ALKS
IPO Date July 16, 1991

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.